SCHEDULE: Knight Therapeutics Reports 19.85% Stake in 60 Degrees Pharmaceuticals
Schedule 13G Filing
Knight Therapeutics Inc. has disclosed beneficial ownership of 658,629 shares, representing 19.85% of the outstanding common stock of 60 Degrees Pharmaceuticals, Inc.
Summary
- Knight Therapeutics Inc. has filed a Schedule 13G, reporting beneficial ownership of 658,629 shares of 60 Degrees Pharmaceuticals, Inc. common stock.
- This holding represents 19.85% of the total outstanding shares.
- The filing is based on 2,659,288 shares outstanding as of May 15, 2026, as per 60 Degrees Pharmaceuticals' Form 10-Q.
- Knight Therapeutics Inc. has sole voting and sole dispositive power over these shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing, as it primarily reports existing ownership without new strategic announcements or financial performance data.
Positives
- Knight Therapeutics Inc. has established a significant ownership stake of 19.85% in 60 Degrees Pharmaceuticals, Inc.
- The reporting person holds sole voting and dispositive power, indicating direct control over their holdings.
Future Outlook
No specific forward-looking statements or guidance were provided in this Schedule 13G filing.
Management Comments
- Knight Therapeutics Inc. certifies that the securities were not acquired or held for the purpose of or with the effect of changing or influencing the control of the issuer, nor in connection with any transaction having that purpose or effect, other than activities solely in connection with a nomination under Rule 240.14a-11.
Industry Context
StockSavvy.ai notes that this Schedule 13G filing by Knight Therapeutics Inc. indicates a substantial passive investment in 60 Degrees Pharmaceuticals, Inc., potentially signaling strategic interest or a significant portfolio allocation within the pharmaceutical sector.
Stakeholder Impact
- Shareholders of 60 Degrees Pharmaceuticals, Inc. are informed of a significant ownership block held by Knight Therapeutics Inc., which may influence future corporate actions or strategic decisions.
- Knight Therapeutics Inc. stakeholders are provided with transparency regarding their investment in 60 Degrees Pharmaceuticals, Inc.
Key Dates
| Date | Description |
|---|---|
| 05/15/2026 | Date of Issuer's quarterly report on Form 10-Q, used for calculating outstanding shares. |
| 07/22/2026 | Date of Event Which Requires Filing of this Statement. |
| 07/28/2026 | Date of Signature on the Schedule 13G filing. |
Keywords
60 Degrees Pharmaceuticals, Knight Therapeutics, Schedule 13G, Beneficial Ownership, Common Stock, Shareholder
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.